The startup develops a microfluidics chip that enables non-viral transfection for CRISPR screening at single donor resolution, requiring 100 times less input material. This technology significantly reduces the time and cost of drug discovery workflows by enhancing lab automation through miniaturization and parallelization.
Funding
$80K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current CRISPR screening methods often require large amounts of input material and are time-consuming and expensive, hindering drug discovery workflows. Traditional transfection methods can also be harsh on cells, affecting experimental results.
Solution
This startup offers a microfluidics-based platform that enables non-viral transfection for CRISPR screening at single-donor resolution, requiring significantly less input material. By miniaturizing and parallelizing the process, the technology enhances lab automation, reducing the time and cost associated with drug discovery. The platform's gentle, non-viral transfection method ensures higher cell viability and more reliable screening results.
Target Audience
The primary customers are drug developers and researchers in the pharmaceutical and biotechnology industries seeking to improve the efficiency and clinical relevance of their drug discovery workflows.
Features
- Microfluidics chip for non-viral transfection
- Enables CRISPR screening at single donor resolution
- Requires 100x less input material compared to traditional methods
- Reduces time and cost of drug discovery workflows by 10x
- Enhances lab automation through miniaturization and parallelization
- Gentle transfection method to maintain cell viability
- Compatible with existing lab automation systems